Andy Ni

Assistant Attending Biostatistician

Office Phone




University of North Carolina at Chapel Hill

Current Research Interests

Dr. Ni’s current methodological research interests include the design and analysis of large-scale observational studies and cancer clinical trials. In his dissertation Dr. Ni developed a regularized variable selection method for case-cohort studies with survival outcome. At MSKCC, he continues to develop efficient variable selection methods under various outcome-dependent sampling designs. These methods are particularly useful for prognostic and predictive biomarker discovery from large cancer databases with high-dimensional gene mutation and expression variables. Dr. Ni primarily collaborates with thoracic and lymphoma oncologists to conduct clinical research. He is currently working on various projects include evaluation of circulating tumor DNA as a novel diagnostic and prognostic tool, identification of predictive biomarkers for response to cancer immunotherapy, and investigation of time to treatment as potential surrogate of overall survival in lymphoma patients. He also participates in the design of clinical trials of different phases.


  1. J.C. Osorio, A. Ni, J.E. Chaft, R. Pollina, M.K. Kasler, D. Stephens, C. Rodriquez, L. Cambridge, H. Rizvi, J. Wolchok, T. Merghoub, C.M. Rudin, S. Fish, and M.D. Hellmann. \Antibody-Mediated Thyroid Dysfunction During T cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer.” To appear in Annals of Oncology, 2016.

  2. A. Drilon, N. Rekhtman, M. Arcila, L. Wang, A. Ni, M. Albano, M.V. Voothuysen, R. Somwar, R. Smith, J. Montecalvo, A. Plodkowski, M. Ginsberg, G. Riely, C.M. Rudin, M. Ladanyi, M. Kris. “A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers”. To appear in Lancet Oncology, 2016.

  3. A. Ni, J. Cai, D. Zeng. “Variable selection for case-cohort studies with failure time outcome”. Biometrika. 2016; 103 (3): 547-562.

  4. A.L. Ho, L. Dunn, E.J. Sherman, M.G. Fury, S.S. Baxi, R. Chandramohan, A. Ni, … & C.S. Sima. “A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma”. Annals of Oncology. 2016 Oct; 27(10): 1902-8.

  5. B.H. Lok, E.E. Gardner, V.E. Schneeberger, A. Ni, P. Desmeules, N. Rekhtman, E. de Stanchina, B.A. Teicher, R. Riaz, S.N. Powell, J.T. Poirier, C.M. Rudin. “PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.” Clin Cancer Res. 2016 Jul 20. [Epub ahead of print].